Pneumagen Ltd’s Recent COVID-19 Data Covered by BBC’s “The Nine”
Pneumagen Ltd Announces Positive Anti–Viral Activity for Novel Glycan Approach in Preventing COVID–19 Infections
Pneumagen Ltd Leverages its Novel Glycan Approach to Target Coronavirus (COVID-19) Infections
Pneumagen Presents Poster on Multivalent Sialic Acid-binding Proteins as a Novel Preventative and Treatment of RSV at RSVVW 2019
Pneumagen Demonstrates Preclinical Proof-of-Concept in Oncology for Neumonco, a Novel Carbohydrate Binding Module
Pneumagen Demonstrates Preclinical Proof-of-Concept for Neumifil™ in Respiratory Syncytial Virus Infections
Pneumagen Appoints Scientific Advisory Board
Publication – Sialic Acid-Binding Protein Sp2CBMTD Protects Mice against Lethal Challenge with Emerging Influenza A (H7N9) Virus
PUBLICATION – Prevention of influenza by targeting host receptors using engineered proteins
Jefferies London Healthcare Conference | November 15th – 17th 2022
BIO-Europe in Leipzig | October 24th – 26th 2022
BIO International Convention in San Diego | June 13th – 16th 2022
Bio€quity Europe in Milan | May 16th – 18th 2022
BioTrinity 2022 in London | April 26th – 27th 2022
BIO-Europe Spring Digital | March 28th – 30th 2022
